Resource Center

Mar 4, 2021
  |  Video

Representation of Efavirenz-mediated Drug-Induced Liver Injury (DILI) Using Quantitative Systems Toxicology (QST)

Diane Longo, Senior Scientist, presents, “Representation of Efavirenz-mediated Drug-Induced Liver Injury (DILI) Using Quantitative Systems Toxicology (QST)”

Efavirenz is a non-nucleoside reverse transcriptase inhibitor (NNRTI) used in combination with other agents to treat human immunodeficiency virus (HIV) infection.   Efavirenz treatment is associated with a low frequency of serum enzyme elevations.   To understand the hepatotoxicity mechanisms underlying clinically observed liver signals, efavirenz was represented in DILIsym®, a QST model of DILI.

This work was previously presented at ACoP 2020 Conference and re-presented at the SLP MIDD+ Virtual Conference March 3-4, 2021

Contact Us About This Video